Sugi Predict

Sugi Predict / Compounds / SCHEMBL359650

SCHEMBL359650

SCHEMBL359650

O=C1CC(NC(=O)OCc2ccccc2)C1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.65
▸ GAA P10253 1/20 0.65
▸ TSHR P16473 1/20 0.62
▸ EPHX1 P07099 1/20 0.58
▸ CA1 P00915 2/20 0.56
▸ CA2 P00918 2/20 0.56
▸ ACHE P22303 2/20 0.56
▸ CTSL P07711 1/20 0.55
▸ CTSB P07858 1/20 0.55
▸ CTSK P43235 1/20 0.55
▸ TLR4 O00206 1/20 0.54
▸ NAAA Q02083 1/20 0.51
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ DPP4 P27487 1/20 0.50
▸ KCNH2 Q12809 1/20 0.50
▸ DPP7 Q9UHL4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL758357 0.88 ALDH1A1 (0.63) ALDH1A1GAATSHREPHX1CA1
SCHEMBL29248505 0.88 ALDH1A1 (0.63) ALDH1A1GAATSHREPHX1CA1
SCHEMBL170233 0.88 ALDH1A1 (0.65) ALDH1A1GAATSHREPHX1CA1
SCHEMBL25531048 0.87 ALDH1A1 (0.60) ALDH1A1GAATSHREPHX1CA1
SCHEMBL1086370 0.87 ALDH1A1 (0.60) ALDH1A1GAATSHREPHX1CA1
SCHEMBL1932815 0.86 ALDH1A1 (0.63) ALDH1A1GAATSHREPHX1CA1
SCHEMBL23898987 0.86 CYP3A4 (0.63) ALDH1A1GAATSHREPHX1CA1
SCHEMBL4101161 0.86 ALDH1A1 (0.56) ALDH1A1GAATSHREPHX1CA1
SCHEMBL2207513 0.86 CYP3A4 (0.63) ALDH1A1GAATSHREPHX1CA1
SCHEMBL30440710 0.86 KMT2A (0.54) ALDH1A1GAATSHREPHX1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122038329-A Imine reductase mutant, encoding gene and application thereof 浙江赞源生物技术有限公司 2026-05-15 — — CN disclosed
EP-4735444-A1 BENZYL (3-(METHYL(7H-PYRROLO[2,3-D]PYRIMIDIN-4YL)AMINO)CYCLOBUTYL) CARBAMATE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF ABROCITINIB Moehs Ibérica, S.L. (ES) 2026-05-06 — — EP disclosed
EP-4724430-A1 CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE Flagship Pioneering Innovations VI, LLC (US) 2026-04-15 — — EP disclosed
US-20250332266-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BEIGENE SWITZERLAND GMBH (CH) 2025-10-30 — — US disclosed
EP-4572755-A2 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 — — EP disclosed
WO-2025090514-A1 COVALENT SARM1 INHIBITORS NURA BIO, INC. (US) 2025-05-01 — — WO disclosed
US-12281102-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 — — US disclosed
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-04-10 — — US disclosed
WO-2025003177-A1 BENZYL (3-(METHYL(7H-PYRROLO[2,3-D]PYRIMIDIN-4YL)AMINO)CYCLOBUTYL) CARBAMATE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF ABROCITINIB MOEHS IBERICA, S.L. (ES) 2025-01-02 — — WO disclosed
WO-2024254396-A1 CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE FLAGSHIP PIONEERING INNOVATIONS, VI, LLC (US) 2024-12-12 — — WO disclosed
WO-2007062308-A2 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 — — WO disclosed
WO-2007062308-A2 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 — — WO disclosed
EP-1256578-B1 Thiazole derivatives and their use as cdk inhibitors PFIZER PROD INC (US) 2006-01-11 — — EP disclosed
US-20040192746-A1 Thiazole derivatives PFIZER INC 2004-09-30 — — US disclosed
US-6720427-B2 USED TO TREAT ABNORMAL CELL GROWTH AND CENTRAL NERVOUS SYSTEM DISORDERS PFIZER INC. 2004-04-13 — — US disclosed
US-20030078252-A1 Thiazole derivatives PFIZER INC. 2003-04-24 — — US disclosed
EP-1256578-A1 Thiazole derivatives and their use as cdk inhibitors Pfizer Products Inc. (US) 2002-11-13 — — EP disclosed
US-5246931-A Triazine-substituted cyclobutane derivatives; viricides; side effect reduction BRISTOL-MYERS SQUIBB COMPANY (US) 1993-09-21 — — US disclosed
US-5153352-A Viricides and antitumor agent BRISTOL-MYERS SQUIBB COMPANY (US) 1992-10-06 — — US disclosed
EP-0366059-A2 Carbocyclic nucleoside analogs BRISTOL-MYERS SQUIBB COMPANY (US) 1990-05-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12281102-B2 Inhibitors of APOL1 and methods of using same APOL1, APOB, NPC1L1 ALDH1A1 2069/4885GAA 912/4885TSHR 4028/4885
US-20030078252-A1 Thiazole derivatives CDK1, CDKL1, CDK5 ALDH1A1 689/4885GAA 3277/4885TSHR 556/4885
US-20250332266-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE EGFR, ERBB2, ERBB3 ALDH1A1 3644/4885GAA 2187/4885TSHR 2376/4885
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 ALDH1A1 4008/4885GAA 2658/4885TSHR 3971/4885
US-20040192746-A1 Thiazole derivatives CDK1, CDKL1, CDK5 ALDH1A1 689/4885GAA 3277/4885TSHR 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.